Impact of Rifabutin on the Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor

Phase 4 Completed 6 enrolled University of Southern California

NaSingle-groupOpen-labelOther

Summary

This is a prospective, single-center, fixed-sequence, nonrandomized, open-label study in healthy adults to investigate the impact of rifabutin on the pharmacokinetics of trikafta.

Timeline

Start: 2022-05-09
Primary completion: 2024-05-30
Completion: 2024-05-30

Publications

Sanders M, Hong E, Chung PS, Rao AP, Cohn W, Beringer P. Evaluation of the drug interaction between rifabutin and elexacaftor/tezacaftor/ivacaftor (ETI). J Cyst Fibros. 2026 Jan;25(1):151-157. doi: 10.1016/j.jcf.2025.09.002. Epub 2025 Sep 16.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ivacaftor	Other / unclassified	75 mg	Oral
Subject	Rifabutin	Small molecule	300 mg	Oral
Subject	elexacaftor	Small molecule	100 mg	Oral
Subject	tezacaftor	Other / unclassified	50 mg	Oral

Indications

No indication recorded.